UMIN-CTR Clinical Trial

Recruitment status Preinitiation
Unique ID issued by UMIN UMIN000045111
Receipt No. R000051379
Scientific Title The analgesic efficacy of constant fentanyl infusion and IV acetaminophen with transversus abdominis plane block in thoracoscopic esophagectomy: a randomized controlled trial.
Date of disclosure of the study information 2021/08/10
Last modified on 2021/08/10 (Ver. 1)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title The analgesic efficacy of constant fentanyl infusion and IV acetaminophen with transversus abdominis plane block in thoracoscopic esophagectomy: a randomized controlled trial.
Acronym The analgesic efficacy of constant fentanyl infusion and IV acetaminophen with transversus abdominis plane block in thoracoscopic esophagectomy: a randomized controlled trial.
Scientific Title The analgesic efficacy of constant fentanyl infusion and IV acetaminophen with transversus abdominis plane block in thoracoscopic esophagectomy: a randomized controlled trial.
Scientific Title:Acronym The analgesic efficacy of constant fentanyl infusion and IV acetaminophen with transversus abdominis plane block in thoracoscopic esophagectomy: a randomized controlled trial.
Region
Japan

Condition
Condition esophageal cancer
Classification by specialty
Gastrointestinal surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 We investigated the possibility that continuous intravenous fentanyl and IV acetaminophen with transversus abdominis plane block could replace epidural anesthesia in thoracoscopic esophageal surgery.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Numerical Rating Scale (NRS) at postoperative day 1 and 3 and 5.
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Cluster
Blinding Open -no one is blinded
Control Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Epi group : The epidural catheter is inserted between the 8th and 9th vertebrae. 100 ml of 0.25% levobupivacaine, 20 ml of fentanyl, and 80 ml of saline are infused continuously at 2-6 ml/hr. After completion of the medication, 100 ml of 0.25% levobupivacaine and 100 ml of saline are added and continued until the 5POD.
Interventions/Control_2 TAP+FA group : Intraoperative transversus abdominis plane block is performed with 40 ml of 0.5% levobupivacaine. Fentanyl IV-PCA (0.025mg/ml, lockout time 10 min) and IV acetaminophen 1000 mg every 6 hours are administered immediately before the end of surgery and continued until the 5POD.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
75 years-old >
Gender Male and Female
Key inclusion criteria 1) Patients with esophageal cancer who are hospitalized or attending the Department of Gastroenterology and General Surgery, Showa University Hospital, and who have undergone radical thoracoscopic subtotal esophagectomy
2) Patients whose age at the time of consent acquisition is between 20 and 75 years old.
3) Patients who have given written consent to participate in this study.
Key exclusion criteria (1) Patients with contraindications to the administration of levobupivacaine, fentanyl, or acetaminophen.
(2) Patients who are at risk for epidural anesthesia catheter insertion or who have difficulty in insertion.
(3) Patients who have difficulty in interviewing for postoperative pain assessment (dementia, postoperative intubation status, etc.).
(4) Patients with serious hepatic, renal, or cardiac disorders that may affect the safety assessment of the drug.
5) Patients with additional painful procedures such as insertion of additional thoracic drains in the postoperative course, or with postoperative complications that affect postoperative pain.
(6) Patients who have been administered anticoagulants before surgery.
(7) Patients deemed ineligible by the research physician.
Target sample size 60

Research contact person
Name of lead principal investigator
1st name Tomotake
Middle name
Last name Ariyoshi
Organization SHOWA University
Division name General and Gastroenterological Surgery
Zip code 1428555
Address 1-5-8 Hatanodai, Shinagawa, Tokyo
TEL 0337848541
Email tariyoshi@med.showa-u.ac.jp

Public contact
Name of contact person
1st name Tomotake
Middle name
Last name Ariyoshi
Organization SHOWA University
Division name General and Gastroenterological Surgery
Zip code 1428555
Address 1-5-8 Hatanodai, Shinagawa, Tokyo
TEL 0337848541
Homepage URL
Email tariyoshi@med.showa-u.ac.jp

Sponsor
Institute SHOWA University
Institute
Department

Funding Source
Organization SHOWA University
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Showa University Medical Ethics Organization
Address 1-5-8 Hatanodai, Shinagawa, Tokyo
Tel 0337848129
Email m-rinri@ofc.showa-u.ac.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2021 Year 08 Month 10 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Preinitiation
Date of protocol fixation
2020 Year 08 Month 10 Day
Date of IRB
2021 Year 05 Month 07 Day
Anticipated trial start date
2021 Year 08 Month 11 Day
Last follow-up date
2023 Year 03 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2021 Year 08 Month 10 Day
Last modified on
2021 Year 08 Month 10 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051379